USPI's surgical cases fell 1.2% in Q2. HCA's outpatient surgeries fell 3.4%. Price carried both.

Surgical case counts went down in the second quarter of 2026 at HCA’s hospitals and outpatient sites and at USPI’s surgery centers. Both declines were steeper than the quarter before. Both companies grew revenue anyway.

That combination is worth sitting with, because it is not the story the first quarter appeared to tell. The Q1 read across the sector — ours included — was hospital outpatient surgery shrinking while dedicated ambulatory platforms grew. That was true of revenue and of margin. It was not true of cases, and the Q2 filings make that plain: USPI’s same-facility cases were already down 0.3% in the first quarter. Tenet leads its release with revenue, so the case line is easy to miss. Two quarters in, it is not.

The three numbers

United Surgical Partners International — Tenet’s ambulatory segment, with interests in 538 ambulatory surgery centers and 26 surgical hospitals across 37 states — reported that “surgical business same-facility system-wide net patient service revenues increased 5.0% in second quarter 2026 compared to second quarter 2025, with cases down 1.2% and net revenue per case up 6.3%,” in the earnings release Tenet filed with the SEC on July 23. The release attributes the per-case growth to “higher acuity and favorable service mix.”

HCA reported that “same facility inpatient surgeries declined 2.3 percent, and same facility outpatient surgeries declined 3.4 percent in the second quarter of 2026,” in the release it filed on July 24. Same-facility revenue per equivalent admission rose 6.4 percent.

Surgery Partners reported same-facility cases up 0.3% against same-facility revenue up 5.0%, with revenue per case up 4.8%, in the results it filed on August 10 — our coverage of that quarter is here. It is the only one of the three with case growth, and 0.3% is flat by any practical reading.

A necessary caution before stacking these against each other: they are not the same basket. HCA states it operated 190 hospitals and roughly 2,600 ambulatory sites of care as of June 30 — surgery centers, freestanding emergency rooms, urgent care and physician clinics, in 19 states and the U.K. — so its outpatient surgery line spans hospital outpatient departments and its own ambulatory sites, not one setting. USPI’s “same-facility system-wide surgical cases” covers consolidated and unconsolidated ASCs plus 26 surgical hospitals. Surgery Partners defines same-facility as “cases and revenues from our consolidated and non-consolidated surgical facilities (excluding facilities acquired in new markets or divested during the current and prior periods).” The direction of each is comparable; the precise magnitudes are not strictly. Note too that HCA’s 6.4% is revenue per equivalent admission, a different denominator from revenue per case, and it does not belong in a column with USPI’s 6.3% or Surgery Partners’ 4.8%.

Both declines got steeper

The trend matters more than any single quarter, and on both sides it points the same way.

USPI’s case decline in Q1 was 0.3%, against revenue up 5.3% and revenue per case up 5.6%, per Tenet’s first-quarter release. At 1.2%, the Q2 decline is four times that rate. HCA’s outpatient surgery decline was 1.7% in Q1, per its first-quarter release; at 3.4%, the Q2 decline is exactly twice it.

The obvious deflationary explanation — fewer business days in the quarter — does not hold. Tenet reports the same metric on a same-business-day basis, and on that basis USPI’s cases were also down 1.2%. Whatever moved, it was not the calendar.

Nor is this general demand weakness. HCA’s same-facility admissions rose 2.5% in the quarter, equivalent admissions rose 2.7%, and emergency room visits rose 3.6%. Patients kept coming; surgery specifically did not keep up. Both HCA surgical lines fell while every medical volume line rose.

Where the cases went is not in these filings

Here is what we cannot tell you, and we would rather say so than guess.

If HCA’s outpatient surgeries are down 3.4% and USPI’s cases are down 1.2%, the cases are not simply moving from the first to the second. Several explanations are consistent with the filings: the total case pool may have grown more slowly or shrunk; volume may be landing at independent ASCs and physician-office settings that file no quarterly report; or it may be going to operators outside these three. Nothing in these four earnings releases distinguishes between those. Anyone who tells you which one it is this quarter is inferring, not reporting.

What the filings do settle is that the sector’s revenue growth in Q2 was priced, not counted. Every operator here grew revenue per unit of work — 6.3% per case at USPI, 4.8% per case at Surgery Partners, 6.4% per equivalent admission at HCA — and that is what carried the quarter.

The economics held, which is the point

None of this showed up as a bad quarter. USPI’s Ambulatory Care Adjusted EBITDA was $542 million, up 8.8% over Q2 2025. Tenet’s release is titled “Tenet Reports Strong Second Quarter 2026 Results; Raises 2026 Financial Outlook,” and net income available to common shareholders was $826 million, or $9.84 per diluted share, against $288 million and $3.14 a year earlier.

Chairman and CEO Saum Sutaria, M.D., framed the quarter this way in the release: “Strong same-store revenue growth and effective expense management drove our fundamental outperformance in the second quarter of 2026 compared to our original assumptions.” He added that Tenet is “actively navigating current industry dynamics through excellent operational execution, investments in innovation, and a continued focus on higher acuity services to sustain growth, margins and significant free cash flow.”

Read that against the case count and the strategy is explicit. Higher acuity is the plan. A platform that moves its mix toward more complex, better-reimbursed procedures can grow revenue and margin on flat or declining case volume for a long while — and USPI has now done it for two quarters running.

What it means for anyone pricing an ASC

For operators and for anyone underwriting a center, the composition of that growth is the whole question. Tenet has told investors its ASC acquisitions enter at 8–10x and improve to an effective 5–7x within three years, a framework we examined in June. Those improvement assumptions are built on the acquirer’s ability to add volume to a center it has bought. Two consecutive quarters of negative same-facility case growth at the buyer’s own existing portfolio is a direct question mark over that mechanism, and it is the number a seller’s advisor should expect to be asked about.

One more fact from the same two releases points the same direction. USPI held interests in 541 ambulatory surgery centers (407 consolidated) and 26 surgical hospitals at March 31. At June 30 it held interests in 538 ambulatory surgery centers (405 consolidated) and the same 26 surgical hospitals, in 37 states. That is a net decrease of three ASC interests, in the quarter following one in which USPI told investors it had spent $125 million to buy seven centers. Neither release explains the change, and neither breaks out second-quarter acquisition spend against the $250 million annual target the company has stated publicly, so we are not going to tell you why it happened. We are going to watch the third quarter.

The number to watch in October is simple: whether USPI posts a third consecutive quarter of same-facility case decline. Two quarters is a pattern worth pricing. Three would make the acuity strategy the whole story rather than a favorable tailwind on top of a growing base.